Dishman Carbogen Amcis Limited

Financial Health of Dishman Carbogen Amcis Limited

Comparing to competitors in the Biotechnology industry

Industry Rankings

Dishman Carbogen Amcis Limited
Buy, Hold or Sell?

Should you buy, hold or sell Dishman Carbogen Amcis Limited?

I guess you are interested in Dishman Carbogen Amcis Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Dishman Carbogen Amcis Limited

Let's start. I'm going to help you getting a better view of Dishman Carbogen Amcis Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Show more...

Company's Financial Health
A deep dive into the books. How are the numbers doing? Is Dishman Carbogen Amcis Limited even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
Market Valuation
Finally, you now have an insight of how Dishman Carbogen Amcis Limited is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Dishman Carbogen Amcis Limited. The closing price on 2022-12-02 was INR97.85 per share. Is the company over- or underpriced?
Key Performance Indicators
A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.

Dishman Carbogen Amcis Limited Daily Candlestick Chart

Summary

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is not making a profit/loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating inefficient.
The company is less efficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Dishman Carbogen Amcis Limited.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Dishman Carbogen Amcis Limited earns for each ₹1 of revenue.

Above 10% is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
A Net Profit Margin of -1.6% means that ₹-0.02 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Dishman Carbogen Amcis Limited:

The MRQ is -1.6%. The company is making a loss. -1
The TTM is -0.6%. The company is not making a profit/loss.

Trends

Current period		Compared to		+/-
MRQ	-1.6%	TTM	-0.6%	-1.0%
TTM	-0.6%	YOY	-5.9%	+5.3%
TTM	-0.6%	5Y	3.4%	-4.0%
5Y	3.4%	10Y	5.9%	-2.5%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-1.6%	-223.6%	+222.0%
TTM	-0.6%	-281.7%	+281.1%
YOY	-5.9%	-344.8%	+338.9%
5Y	3.4%	-450.1%	+453.5%
10Y	5.9%	-541.0%	+546.9%

Measures how much net profit Dishman Carbogen Amcis Limited earns for each ₹1 of revenue.

Revenue is the amount of profit Dishman Carbogen Amcis Limited generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you ₹3. The company does not earn ₹3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is ₹1.5.

The ₹3 you pay for a cup of coffee is called revenue.
The ₹1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Dishman Carbogen Amcis Limited earns for each ₹1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each ₹1 in sales, Dishman Carbogen Amcis Limited makes more profit. This shows the investor how efficiently Dishman Carbogen Amcis Limited is operating in general and compared to other companies in the same industry. Dishman Carbogen Amcis Limited operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Dishman Carbogen Amcis Limited. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Dishman Carbogen Amcis Limited is -0.02. This means that Dishman Carbogen Amcis Limited earned ₹-0.02 for each ₹1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -223.6%.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Dishman Carbogen Amcis Limited with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Dishman Carbogen Amcis Limited sells assets (profit will increase while costs remain the same).
It won’t show what part of Dishman Carbogen Amcis Limited is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Dishman Carbogen Amcis Limited

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Dishman Carbogen Amcis Limited = -100,500
Total revenue MRQ Dishman Carbogen Amcis Limited = 6,139,600
₹-100,500 / ₹6,139,600 = -0.02 or -1.6%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Dishman Carbogen Amcis Limited is using its assets to generate profit.

Above 5% is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
-0.1% Return on Assets means that Dishman Carbogen Amcis Limited generated ₹0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Dishman Carbogen Amcis Limited:

The MRQ is -0.1%. Using its assets, the company is very inefficient in making profit. -2
The TTM is 0.0%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-0.1%	TTM	0.0%	-0.1%
TTM	0.0%	YOY	-0.4%	+0.3%
TTM	0.0%	5Y	0.2%	-0.3%
5Y	0.2%	10Y	0.6%	-0.4%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-0.1%	-9.9%	+9.8%
TTM	0.0%	-8.9%	+8.9%
YOY	-0.4%	-9.3%	+8.9%
5Y	0.2%	-11.7%	+11.9%
10Y	0.6%	-12.7%	+13.3%

Shows how efficient Dishman Carbogen Amcis Limited is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Dishman Carbogen Amcis Limited is using its resources to generate profit. If the return on assets (-0.1%) from Dishman Carbogen Amcis Limited are higher than the Biotechnology mean (-9.9%) that means Dishman Carbogen Amcis Limited is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Dishman Carbogen Amcis Limited is -0.1%. This means the company generated ₹0.00 for each ₹1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -9.9%.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Dishman Carbogen Amcis Limited

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Dishman Carbogen Amcis Limited = -100,500
Total assets MRQ (balance sheet) from Dishman Carbogen Amcis Limited = 88,264,400
-100,500 / 88,264,400 = 0.00 or -0.1%

ROA is an important ratio as it will tell you how effectively Dishman Carbogen Amcis Limited is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Dishman Carbogen Amcis Limited is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
-0.2% Return on Equity means Dishman Carbogen Amcis Limited generated ₹0.00 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Dishman Carbogen Amcis Limited:

The MRQ is -0.2%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -0.1%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-0.2%	TTM	-0.1%	-0.1%
TTM	-0.1%	YOY	-0.5%	+0.5%
TTM	-0.1%	5Y	0.3%	-0.4%
5Y	0.3%	10Y	1.3%	-1.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-0.2%	-12.0%	+11.8%
TTM	-0.1%	-11.5%	+11.4%
YOY	-0.5%	-10.8%	+10.3%
5Y	0.3%	-14.2%	+14.5%
10Y	1.3%	-15.2%	+16.5%

Shows how efficient Dishman Carbogen Amcis Limited is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Dishman Carbogen Amcis Limited is -0.2%. This means Dishman Carbogen Amcis Limited generated ₹0.00 for each ₹1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -12.0%.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if Dishman Carbogen Amcis Limited existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Dishman Carbogen Amcis Limited

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Dishman Carbogen Amcis Limited = -100,500
Shareholders equity (balance sheet) MRQ Dishman Carbogen Amcis Limited = 55,539,900
-100,500 / 55,539,900 = 0.00 or -0.2%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Dishman Carbogen Amcis Limited.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Dishman Carbogen Amcis Limited is operating .

Measures how much profit Dishman Carbogen Amcis Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
An Operating Margin of -0.2% means the company generated ₹0.00 for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Dishman Carbogen Amcis Limited:

The MRQ is -0.2%. The company is operating very inefficient. -2
The TTM is 0.2%. The company is operating inefficient. -1

Trends

Current period		Compared to		+/-
MRQ	-0.2%	TTM	0.2%	-0.3%
TTM	0.2%	YOY	2.4%	-2.2%
TTM	0.2%	5Y	8.6%	-8.4%
5Y	8.6%	10Y	12.7%	-4.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-0.2%	-207.3%	+207.1%
TTM	0.2%	-271.0%	+271.2%
YOY	2.4%	-325.9%	+328.3%
5Y	8.6%	-454.0%	+462.6%
10Y	12.7%	-537.1%	+549.8%

Measures how efficient Dishman Carbogen Amcis Limited is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Dishman Carbogen Amcis Limited is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Dishman Carbogen Amcis Limited is -0.2%. This means that Dishman Carbogen Amcis Limited earned ₹0.00 for each ₹1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -207.3%.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Dishman Carbogen Amcis Limited

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Dishman Carbogen Amcis Limited = -9,700
Total revenue MRQ Dishman Carbogen Amcis Limited = 6,139,600
₹-9,700 / ₹6,139,600 = 0.00 or -0.2%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Dishman Carbogen Amcis Limited is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 0.26 means that the operating costs are ₹0.26 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Dishman Carbogen Amcis Limited:

The MRQ is 0.263. The company is very efficient in keeping operating costs low. +2
The TTM is 0.821. The company is less efficient in keeping operating costs low.

Trends

Current period		Compared to		+/-
MRQ	0.263	TTM	0.821	-0.559
TTM	0.821	YOY	0.968	-0.147
TTM	0.821	5Y	0.886	-0.064
5Y	0.886	10Y	0.867	+0.019

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.263	2.871	-2.608
TTM	0.821	3.504	-2.683
YOY	0.968	3.604	-2.636
5Y	0.886	5.132	-4.246
10Y	0.867	6.371	-5.504

Measures how efficient Dishman Carbogen Amcis Limited is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Dishman Carbogen Amcis Limited is 26.3%. This means that Dishman Carbogen Amcis Limited earned ₹0.26 for each ₹1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 2.87.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Dishman Carbogen Amcis Limited

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(1,612,100 +) \ 6,139,600 = 0.26

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Dishman Carbogen Amcis Limited.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Dishman Carbogen Amcis Limited is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 1.18 means the company has ₹1.18 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Dishman Carbogen Amcis Limited:

The MRQ is 1.180. The company is just able to pay all its short-term debts.
The TTM is 0.943. The company is just not able to pay all its short-term debts. -1

Trends

Current period		Compared to		+/-
MRQ	1.180	TTM	0.943	+0.238
TTM	0.943	YOY	0.642	+0.301
TTM	0.943	5Y	0.683	+0.259
5Y	0.683	10Y	0.603	+0.080

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.180	5.117	-3.937
TTM	0.943	5.755	-4.812
YOY	0.642	5.854	-5.212
5Y	0.683	6.511	-5.828
10Y	0.603	6.222	-5.619

Measures if Dishman Carbogen Amcis Limited is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Dishman Carbogen Amcis Limited if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Dishman Carbogen Amcis Limited is 1.18. This means Dishman Carbogen Amcis Limited has ₹1.18 in assets for each ₹1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 5.12.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Dishman Carbogen Amcis Limited

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
19,120,600 \ 16,198,300) = 1.18

The current ratio measures if Dishman Carbogen Amcis Limited is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Dishman Carbogen Amcis Limited is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Dishman Carbogen Amcis Limited does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Dishman Carbogen Amcis Limited is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Dishman Carbogen Amcis Limited is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
A Quick Ratio of 0.70 means the company can pay off ₹0.70 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Dishman Carbogen Amcis Limited:

The MRQ is 0.699. The company is just not able to pay all its short-term debts with the most liquid assets. -1
The TTM is 0.514. The company is just not able to pay all its short-term debts with the most liquid assets. -1

Trends

Current period		Compared to		+/-
MRQ	0.699	TTM	0.514	+0.185
TTM	0.514	YOY	0.412	+0.101
TTM	0.514	5Y	0.378	+0.136
5Y	0.378	10Y	0.238	+0.140

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.699	4.284	-3.585
TTM	0.514	4.664	-4.150
YOY	0.412	4.787	-4.375
5Y	0.378	5.218	-4.840
10Y	0.238	5.182	-4.944

Measures if Dishman Carbogen Amcis Limited is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Dishman Carbogen Amcis Limited can pay off its short term debts. This shows if Dishman Carbogen Amcis Limited can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Dishman Carbogen Amcis Limited is 0.70. This means that Dishman Carbogen Amcis Limited can pay off ₹0.70 for each ₹1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 4.28.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Dishman Carbogen Amcis Limited

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Dishman Carbogen Amcis Limited: (4,335,700 + 1,645,900 +5,338,200) / 16,198,300 = 0.70

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Dishman Carbogen Amcis Limited.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Dishman Carbogen Amcis Limited assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Dishman Carbogen Amcis Limited to Biotechnology industry mean.
A Debt to Asset Ratio of 0.37 means that Dishman Carbogen Amcis Limited assets are financed with 37.1% credit (debt) and the remaining percentage (100% - 37.1%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Dishman Carbogen Amcis Limited:

The MRQ is 0.371. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.352. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.371	TTM	0.352	+0.019
TTM	0.352	YOY	0.310	+0.042
TTM	0.352	5Y	0.306	+0.046
5Y	0.306	10Y	0.400	-0.095

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.371	0.278	+0.093
TTM	0.352	0.277	+0.075
YOY	0.310	0.306	+0.004
5Y	0.306	0.367	-0.061
10Y	0.400	0.403	-0.003

Measures how much % of Dishman Carbogen Amcis Limited assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Dishman Carbogen Amcis Limited than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Dishman Carbogen Amcis Limited to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Dishman Carbogen Amcis Limited is 0.37. This means means that Dishman Carbogen Amcis Limited is financed with 37.1% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 511.7%.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Dishman Carbogen Amcis Limited has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Dishman Carbogen Amcis Limited

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
32,724,500 \ 88,264,400 = 37.1% or 0.37.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Dishman Carbogen Amcis Limited is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
A Debt to Equity ratio of 58.9% means that company has ₹0.59 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Dishman Carbogen Amcis Limited:

The MRQ is 0.589. The company is very able to pay all its debts with equity. +2
The TTM is 0.543. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.589	TTM	0.543	+0.046
TTM	0.543	YOY	0.450	+0.094
TTM	0.543	5Y	0.443	+0.101
5Y	0.443	10Y	0.745	-0.303

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.589	0.315	+0.274
TTM	0.543	0.317	+0.226
YOY	0.450	0.319	+0.131
5Y	0.443	0.403	+0.040
10Y	0.745	0.462	+0.283

Measures if Dishman Carbogen Amcis Limited is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Dishman Carbogen Amcis Limited is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Dishman Carbogen Amcis Limited is 0.59. This means that Dishman Carbogen Amcis Limited can pay off ₹0.59 for each ₹1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.32.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Dishman Carbogen Amcis Limited

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
32,724,500 \ 55,539,900 = 0.59 or 58.9%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Dishman Carbogen Amcis Limited

2. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Dishman Carbogen Amcis Limited generates.

Above 15 is considered overpriced but always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
A PE ratio of -150.39 means the investor is paying ₹-150.39 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Dishman Carbogen Amcis Limited:

The EOD is -152.649. Company is losing money. -2
The MRQ is -150.387. Company is losing money. -2
The TTM is -256.353. Company is losing money. -2

Trends

Current period		Compared to		+/-
EOD	-152.649	MRQ	-150.387	-2.262
MRQ	-150.387	TTM	-256.353	+105.966
TTM	-256.353	YOY	85.797	-342.150
TTM	-256.353	5Y	16.278	-272.631
5Y	16.278	10Y	11.234	+5.044

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-152.649	-8.986	-143.663
MRQ	-150.387	-9.792	-140.595
TTM	-256.353	-16.243	-240.110
YOY	85.797	-20.876	+106.673
5Y	16.278	-16.665	+32.943
10Y	11.234	-14.732	+25.966

Measures how much money you pay for each share for every ₹1 in earnings Dishman Carbogen Amcis Limited generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Dishman Carbogen Amcis Limited to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Dishman Carbogen Amcis Limited is -150.39. This means the investor is paying ₹-150.39 for every ₹1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -9.79.
What is the trend?
The trend is important because it shows you how Dishman Carbogen Amcis Limited is performing over time. The most recent quarter might be important if Dishman Carbogen Amcis Limited released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Dishman Carbogen Amcis Limited up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Dishman Carbogen Amcis Limited

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
-100,500 \ 156,783 = EPS
PE ratio MRQ = -150.39

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Dishman Carbogen Amcis Limited.

Lower is better.
A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Dishman Carbogen Amcis Limited:

The MRQ is 107.496. Seems overpriced? -1
The TTM is 171.346. Seems overpriced? -1

Trends

Current period		Compared to		+/-
MRQ	107.496	TTM	171.346	-63.850
TTM	171.346	YOY	-128.802	+300.148
TTM	171.346	5Y	63.773	+107.573
5Y	63.773	10Y	68.295	-4.521

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	107.496	-0.032	+107.528
TTM	171.346	0.004	+171.342
YOY	-128.802	0.016	-128.818
5Y	63.773	0.006	+63.767
10Y	68.295	0.003	+68.292

PEG Ratio	Meaning
0.5	You can buy the stock cheap based on future growth
1	You pay a fair price based on future growth
2	The stock is overpriced based on future growth

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Dishman Carbogen Amcis Limited is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 0.27 means the investor is paying ₹0.27 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Dishman Carbogen Amcis Limited:

The EOD is 0.276. Very good. +2
The MRQ is 0.272. Very good. +2
The TTM is 0.415. Very good. +2

Trends

Current period		Compared to		+/-
EOD	0.276	MRQ	0.272	+0.004
MRQ	0.272	TTM	0.415	-0.142
TTM	0.415	YOY	0.453	-0.038
TTM	0.415	5Y	0.537	-0.123
5Y	0.537	10Y	0.304	+0.233

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	0.276	1.835	-1.559
MRQ	0.272	2.006	-1.734
TTM	0.415	2.774	-2.359
YOY	0.453	3.453	-3.000
5Y	0.537	2.713	-2.176
10Y	0.304	2.402	-2.098

2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Dishman Carbogen Amcis Limited compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	0.322	-3.442	+1169%	-1.009	+414%	2.572	-87%	7.601	-96%
Book Value Growth	-	-	0.988	0.988	+0%	0.988	+0%	0.988	0%	0.988	0%
Book Value Per Share	-	-	354.247	358.010	-1%	365.846	-3%	347.703	+2%	232.525	+52%
Book Value Per Share Growth	-	-	0.001	-0.010	+1177%	-0.003	+412%	0.007	-88%	0.033	-97%
Current Ratio	-	-	1.180	0.943	+25%	0.642	+84%	0.683	+73%	0.603	+96%
Debt To Asset Ratio	-	-	0.371	0.352	+5%	0.310	+20%	0.306	+21%	0.400	-7%
Debt To Equity Ratio	-	-	0.589	0.543	+8%	0.450	+31%	0.443	+33%	0.745	-21%
Dividend Per Share	-	-	-	-	0%	-	0%	0.020	-100%	0.118	-100%
Eps	-	-	-0.641	-0.243	-62%	-1.965	+207%	1.028	-162%	1.507	-143%
Eps Growth	-	-	-1.399	-0.668	-52%	1.656	-184%	0.151	-1026%	0.179	-883%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Net Profit Margin	-	-	-0.016	-0.006	-63%	-0.059	+258%	0.034	-148%	0.059	-128%
Operating Margin	-	-	-0.002	0.002	-201%	0.024	-107%	0.086	-102%	0.127	-101%
Operating Ratio	-	-	0.263	0.821	-68%	0.968	-73%	0.886	-70%	0.867	-70%
Pb Ratio	0.276	+1%	0.272	0.415	-34%	0.453	-40%	0.537	-49%	0.304	-11%
Pe Ratio	-152.649	-2%	-150.387	-256.353	+70%	85.797	-275%	16.278	-1024%	11.234	-1439%
Peg Ratio	-	-	107.496	171.346	-37%	-128.802	+220%	63.773	+69%	68.295	+57%
Price Per Share	97.850	+1%	96.400	148.913	-35%	165.575	-42%	183.023	-47%	102.517	-6%
Price To Total Gains Ratio	303.983	+1%	299.478	130.775	+129%	26.334	+1037%	135.667	+121%	133.959	+124%
Profit Growth	-	-	-100.491	2.955	-3501%	2.047	-5009%	50.330	-300%	73.844	-236%
Quick Ratio	-	-	0.699	0.514	+36%	0.412	+69%	0.378	+85%	0.238	+194%
Return On Assets	-	-	-0.001	0.000	-63%	-0.004	+228%	0.002	-149%	0.006	-118%
Return On Equity	-	-	-0.002	-0.001	-58%	-0.005	+200%	0.003	-157%	0.013	-114%
Revenue Growth	-	-	0.989	0.989	+0%	0.988	+0%	0.988	+0%	0.988	+0%
Total Gains Per Share	-	-	0.322	-3.442	+1169%	-1.009	+414%	2.592	-88%	7.719	-96%
Total Gains Per Share Growth	-	-	1.000	-0.599	+160%	0.761	+31%	-29.742	+3074%	-19.837	+2084%
Usd Book Value	-	-	683140770.000	690398077.500	-1%	708472005.000	-4%	678392539.500	+1%	455157920.385	+50%
Usd Book Value Change Per Share	-	-	0.004	-0.042	+1169%	-0.012	+414%	0.032	-87%	0.093	-96%
Usd Book Value Per Share	-	-	4.357	4.404	-1%	4.500	-3%	4.277	+2%	2.860	+52%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	0.000	-100%	0.001	-100%
Usd Eps	-	-	-0.008	-0.003	-62%	-0.024	+207%	0.013	-162%	0.019	-143%
Usd Price Per Share	1.204	+1%	1.186	1.832	-35%	2.037	-42%	2.251	-47%	1.261	-6%
Usd Profit	-	-	-1236150.000	-468630.000	-62%	-3809925.000	+208%	2033251.500	-161%	2981118.515	-141%
Usd Revenue	-	-	75517080.000	70283430.000	+7%	61687882.500	+22%	62686704.000	+20%	54596133.000	+38%
Usd Total Gains Per Share	-	-	0.004	-0.042	+1169%	-0.012	+414%	0.032	-88%	0.095	-96%
	EOD	+3 -2	MRQ	TTM	+16 -16	YOY	+22 -10	5Y	+13 -21	10Y	+15 -19

3.2. Fundamental Score

Let's check the fundamental score of Dishman Carbogen Amcis Limited based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-152.649
Price to Book Ratio (EOD)	Between	0-1	0.276
Net Profit Margin (MRQ)	Greater than	0	-0.016
Operating Margin (MRQ)	Greater than	0	-0.002
Quick Ratio (MRQ)	Greater than	1	0.699
Current Ratio (MRQ)	Greater than	1	1.180
Debt to Asset Ratio (MRQ)	Less than	1	0.371
Debt to Equity Ratio (MRQ)	Less than	1	0.589
Return on Equity (MRQ)	Greater than	0.15	-0.002
Return on Assets (MRQ)	Greater than	0.05	-0.001
Total			4/10 (40.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

3.3. Technical Score

Let's check the technical score of Dishman Carbogen Amcis Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	40.673
Ma 20	Greater than	Ma 50	103.783
Ma 50	Greater than	Ma 100	101.416
Ma 100	Greater than	Ma 200	110.258
Open	Greater than	Close	98.600
Total			2/5 (40.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in INR. All numbers in thousands.

Summary

Total Assets	88,264,400
Total Liabilities	32,724,500
Total Stockholder Equity	55,539,900

	As reported
Total Liabilities	32,724,500
Total Stockholder Equity	+ 55,539,900
Total Assets	= 88,264,400

Assets

Total Assets	88,264,400
Total Current Assets	19,120,600
Long-term Assets	19,120,600

Total Current Assets

Total Current Assets (as reported)	19,120,600
Short-term Investments	1,645,900
Net Receivables	5,338,200
Inventory	7,492,700
Other Current Assets	2,076,700
Total Current Assets (calculated)	16,553,500
+/-	2,567,100

Long-term Assets

Long-term Assets (as reported)	0
Property Plant Equipment	29,585,800
Goodwill	35,827,500
Intangible Assets	1,106,800
Long-term Assets (calculated)	66,520,100
+/-	66,520,100

Liabilities & Shareholders' Equity

Total Current Liabilities	16,198,300
Long-term Liabilities	-
Total Stockholder Equity	55,539,900

Total Current Liabilities

Total Current Liabilities (as reported)	16,198,300
Accounts payable	1,955,000
Other Current Liabilities	6,280,900
Total Current Liabilities (calculated)	8,235,900
+/-	7,962,400

Long-term Liabilities

Long-term Liabilities (as reported)	0
Long term Debt Total	12,420,300
Long-term Liabilities (calculated)	12,420,300
+/-	12,420,300

Total Stockholder Equity

Total Stockholder Equity (as reported)	55,539,900
Common Stock	313,600
Other Stockholders Equity	55,226,300
Total Stockholder Equity (calculated)	55,539,900
+/-	0

Other

Cash And Equivalents	2,689,800
Cash and Short Term Investments	4,335,700
Common Stock Shares Outstanding	156,783
Liabilities and Stockholders Equity	88,264,400
Net Tangible Assets	18,605,600

Balance Sheet

Currency in INR. All numbers in thousands.

Trend

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

> Total Assets

0
22,586,762
0
0
0
22,911,117
0
25,429,242
0
25,541,994
0
26,400,753
0
28,089,357
0
28,417,413
0
29,804,800
0
30,861,700
0
65,934,300
0
67,250,300
0
71,764,800
0
76,314,100
0
73,284,600
0
77,746,000
0
82,224,200
0
82,154,200
0
83,246,000
0
85,354,300
0
86,374,500
0
88,264,400

88,264,400

86,374,500

85,354,300

83,246,000

82,154,200

82,224,200

77,746,000

73,284,600

76,314,100

71,764,800

67,250,300

65,934,300

30,861,700

29,804,800

28,417,413

28,089,357

26,400,753

25,541,994

25,429,242

22,911,117

22,586,762

> Total Current Assets

0
6,238,727
0
0
0
6,733,031
0
7,733,959
0
7,604,653
0
8,984,632
0
10,135,257
0
10,176,390
0
11,017,900
0
10,628,600
0
13,330,500
0
14,623,700
0
15,461,500
0
17,106,300
0
15,535,700
0
16,546,200
0
18,049,700
0
17,038,900
0
16,626,400
0
16,657,800
18,387,200
18,387,200
0
19,120,600

19,120,600

18,387,200

16,657,800

16,626,400

17,038,900

18,049,700

16,546,200

15,535,700

17,106,300

15,461,500

14,623,700

13,330,500

10,628,600

11,017,900

10,176,390

10,135,257

8,984,632

7,604,653

7,733,959

6,733,031

6,238,727

Cash And Cash Equivalents

0
240,409
0
0
0
171,382
0
330,594
0
307,171
0
469,345
0
243,162
0
524,336
0
561,400
0
287,600
0
586,100
0
539,700
0
655,200
0
1,646,000
0
763,200
0
959,700
0
1,219,400
0
1,409,400
0
2,435,400
0
1,604,000
0
1,102,400
0
0

1,102,400

1,604,000

2,435,400

1,409,400

1,219,400

959,700

763,200

1,646,000

655,200

539,700

586,100

287,600

561,400

524,336

243,162

469,345

307,171

330,594

171,382

240,409

Short-term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
132,000
0
132,000
0
0
0
3,603,700
0
183,400
0
1,782,300
0
1,223,200
0
1,020,900
0
471,200
0
1,414,300
0
1,347,500
0
1,851,300
0
1,876,600
0
2,942,600
0
3,871,000
0
1,645,900

1,645,900

3,871,000

2,942,600

1,876,600

1,851,300

1,347,500

1,414,300

471,200

1,020,900

1,223,200

1,782,300

183,400

3,603,700

132,000

Net Receivables

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,967,000
0
3,986,100
0
5,821,800
0
5,870,400
0
4,453,000
0
4,293,900
0
6,343,900
0
4,730,500
0
4,145,700
0
3,581,400
5,208,800
5,208,800
0
5,338,200

5,338,200

5,208,800

3,581,400

4,145,700

4,730,500

6,343,900

4,293,900

4,453,000

5,870,400

5,821,800

3,986,100

3,967,000

Other Current Assets

0
3,327,694
0
0
0
3,178,952
0
3,274,316
0
3,064,928
0
3,571,540
0
5,277,491
0
4,585,878
0
5,625,400
0
1,789,700
0
8,295,200
0
7,379,500
0
8,737,500
0
9,231,000
0
8,815,100
0
7,959,200
0
9,414,100
0
7,878,200
0
7,157,900
0
6,281,900
2,699,500
6,962,600
0
2,076,700

2,076,700

6,962,600

2,699,500

6,281,900

7,157,900

7,878,200

9,414,100

7,959,200

8,815,100

9,231,000

8,737,500

7,379,500

8,295,200

1,789,700

5,625,400

4,585,878

5,277,491

3,571,540

3,064,928

3,274,316

3,178,952

3,327,694

> Long-term Assets

0
16,348,035
0
0
0
16,178,086
0
17,695,283
0
17,937,341
0
17,416,121
0
17,954,100
0
18,241,023
0
18,786,900
0
20,233,100
0
52,603,800
0
52,626,600
0
56,303,300
0
59,207,800
0
57,748,900
0
61,199,800
0
64,174,500
0
65,115,300
0
66,619,600
0
68,696,500
0
67,987,300
0
0

67,987,300

68,696,500

66,619,600

65,115,300

64,174,500

61,199,800

57,748,900

59,207,800

56,303,300

52,626,600

52,603,800

20,233,100

18,786,900

18,241,023

17,954,100

17,416,121

17,937,341

17,695,283

16,178,086

16,348,035

Property Plant Equipment

0
12,277,906
0
0
0
12,430,221
0
16,078,460
0
13,366,266
0
15,407,908
0
13,262,816
0
15,813,613
0
13,389,900
0
15,032,300
0
14,648,800
0
15,112,300
0
16,223,400
0
16,968,000
0
16,761,900
0
19,692,000
0
20,929,800
0
21,227,800
0
24,414,600
0
26,001,700
27,868,800
27,868,800
0
29,585,800

29,585,800

27,868,800

26,001,700

24,414,600

21,227,800

20,929,800

19,692,000

16,761,900

16,968,000

16,223,400

15,112,300

14,648,800

15,032,300

13,389,900

15,813,613

13,262,816

15,407,908

13,366,266

16,078,460

12,430,221

12,277,906

Goodwill

0
122,966
0
0
0
2,083,299
0
122,954
0
2,434,037
0
122,954
0
2,313,617
0
134,811
0
2,531,800
0
2,531,800
0
34,551,300
0
34,069,000
0
35,329,500
0
36,607,400
0
34,702,900
0
34,640,700
0
36,847,100
0
36,905,500
0
35,810,100
0
36,187,600
0
36,456,800
0
35,827,500

35,827,500

36,456,800

36,187,600

35,810,100

36,905,500

36,847,100

34,640,700

34,702,900

36,607,400

35,329,500

34,069,000

34,551,300

2,531,800

134,811

2,313,617

122,954

2,434,037

122,954

2,083,299

122,966

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
423,600
0
391,700
0
1,036,800
0
1,843,700
0
1,476,200
0
1,345,400
0
0
0
0
0
0
0
0
0
0
0
0

1,345,400

1,476,200

1,843,700

1,036,800

391,700

423,600

Intangible Assets

0
2,112,718
0
0
0
188,834
0
0
0
39,886
0
0
0
251,032
0
0
0
381,900
0
160,900
0
601,200
0
682,100
0
561,200
0
546,800
0
1,209,600
0
1,193,300
0
1,293,400
0
1,341,100
0
1,566,500
0
1,683,100
0
1,150,900
0
1,106,800

1,106,800

1,150,900

1,683,100

1,566,500

1,341,100

1,293,400

1,193,300

1,209,600

546,800

561,200

682,100

601,200

160,900

381,900

251,032

39,886

188,834

2,112,718

Other Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,101,800
0
2,371,500
0
3,152,400
0
3,241,900
0
2,161,100
0
2,992,600
0
4,215,600
0
4,314,500
0
4,263,800
0
4,259,800
2,192,500
2,192,500
0
2,294,500

2,294,500

2,192,500

4,259,800

4,263,800

4,314,500

4,215,600

2,992,600

2,161,100

3,241,900

3,152,400

2,371,500

3,101,800

> Total Liabilities

0
13,266,870
0
0
0
12,603,090
0
14,349,375
0
13,769,948
0
14,239,492
0
15,711,507
0
15,069,135
0
15,285,400
0
14,086,500
0
17,794,500
0
18,396,300
0
20,691,500
0
22,924,500
0
19,493,700
0
22,933,600
0
24,847,300
0
23,734,200
0
26,257,800
0
27,353,300
0
30,885,100
0
32,724,500

32,724,500

30,885,100

27,353,300

26,257,800

23,734,200

24,847,300

22,933,600

19,493,700

22,924,500

20,691,500

18,396,300

17,794,500

14,086,500

15,285,400

15,069,135

15,711,507

14,239,492

13,769,948

14,349,375

12,603,090

13,266,870

> Total Current Liabilities

0
6,630,884
0
0
0
6,808,841
0
8,550,601
0
8,656,725
0
9,188,856
0
11,047,859
0
9,260,366
0
9,517,000
0
9,381,700
0
9,936,700
0
9,123,800
0
11,777,100
0
13,724,300
0
11,983,000
0
14,053,500
0
15,689,300
0
14,890,100
0
12,488,000
0
13,465,600
14,197,900
14,197,900
0
16,198,300

16,198,300

14,197,900

13,465,600

12,488,000

14,890,100

15,689,300

14,053,500

11,983,000

13,724,300

11,777,100

9,123,800

9,936,700

9,381,700

9,517,000

9,260,366

11,047,859

9,188,856

8,656,725

8,550,601

6,808,841

6,630,884

Short-term Debt

0
2,335,679
0
0
0
4,199,928
0
4,042,178
0
5,003,094
0
3,445,025
0
6,025,027
0
3,438,083
0
5,238,700
0
4,464,500
0
4,895,900
8,940,400
3,739,600
9,510,000
5,698,500
9,182,900
6,179,200
0
6,797,700
0
6,425,800
0
8,801,800
0
7,339,900
0
7,197,700
0
6,704,100
0
7,197,300
0
0

7,197,300

6,704,100

7,197,700

7,339,900

8,801,800

6,425,800

6,797,700

6,179,200

9,182,900

5,698,500

9,510,000

3,739,600

8,940,400

4,895,900

4,464,500

5,238,700

3,438,083

6,025,027

3,445,025

5,003,094

4,042,178

4,199,928

2,335,679

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,940,400
8,940,400
9,510,000
9,510,000
1,585,000
9,182,900
0
0
6,590,900
0
6,061,300
0
8,148,600
0
6,680,900
0
5,424,700
0
6,113,100
0
6,588,300
0
0

6,588,300

6,113,100

5,424,700

6,680,900

8,148,600

6,061,300

6,590,900

9,182,900

1,585,000

9,510,000

8,940,400

Accounts payable

0
1,657,874
0
0
0
1,055,503
0
1,016,523
0
928,665
0
746,753
0
1,514,354
0
828,406
0
869,700
0
881,500
0
856,400
0
707,500
0
1,859,100
0
1,326,700
0
1,945,700
0
2,076,400
0
2,835,200
0
1,794,300
0
1,630,200
0
1,590,300
1,928,900
1,933,700
0
1,955,000

1,955,000

1,933,700

1,928,900

1,590,300

1,630,200

1,794,300

2,835,200

2,076,400

1,945,700

1,326,700

1,859,100

707,500

856,400

881,500

869,700

828,406

1,514,354

746,753

928,665

1,016,523

1,055,503

1,657,874

Other Current Liabilities

0
2,637,331
0
0
0
1,553,410
0
3,491,900
0
2,724,966
0
4,997,078
0
3,508,478
0
4,993,877
0
3,408,600
0
4,035,700
0
3,521,500
0
4,225,300
0
3,576,700
0
5,607,800
0
2,805,100
0
5,177,200
0
3,929,700
0
5,598,200
0
3,518,000
0
5,171,200
3,723,600
5,055,400
0
6,280,900

6,280,900

5,055,400

3,723,600

5,171,200

3,518,000

5,598,200

3,929,700

5,177,200

2,805,100

5,607,800

3,576,700

4,225,300

3,521,500

4,035,700

3,408,600

4,993,877

3,508,478

4,997,078

2,724,966

3,491,900

1,553,410

2,637,331

> Long-term Liabilities

0
6,635,986
0
0
0
5,794,249
0
5,798,774
0
5,113,223
0
5,050,636
0
4,663,648
0
5,808,769
0
5,768,400
0
4,704,800
0
7,857,800
0
9,272,500
0
8,914,400
0
9,200,200
0
7,510,700
0
8,880,100
0
9,158,000
0
8,844,100
0
13,769,800
0
13,887,700
0
16,687,200
0
0

16,687,200

13,887,700

13,769,800

8,844,100

9,158,000

8,880,100

7,510,700

9,200,200

8,914,400

9,272,500

7,857,800

4,704,800

5,768,400

5,808,769

4,663,648

5,050,636

5,113,223

5,798,774

5,794,249

6,635,986

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,624,100
0
4,950,200
0
4,772,600
0
4,666,200
0
8,690,800
0
8,810,300
0
11,101,600
0
12,420,300

12,420,300

11,101,600

8,810,300

8,690,800

4,666,200

4,772,600

4,950,200

3,624,100

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,256,600
0
3,502,000
0
3,664,500
0
4,009,600
0
3,886,600
0
3,929,800
0
4,385,400
0
4,171,900
0
5,079,000
0
5,077,400
5,585,600
5,585,600
0
4,105,900

4,105,900

5,585,600

5,077,400

5,079,000

4,171,900

4,385,400

3,929,800

3,886,600

4,009,600

3,664,500

3,502,000

3,256,600

> Total Stockholder Equity

0
9,319,892
0
0
0
10,308,027
0
11,079,847
0
11,772,046
0
12,161,261
0
12,377,850
0
13,348,278
0
14,515,500
0
16,775,200
0
48,139,800
48,139,800
48,854,000
48,854,000
51,073,300
51,073,300
53,389,600
53,389,600
53,790,900
53,790,900
54,812,300
54,812,300
57,376,900
0
58,420,000
0
56,988,200
0
58,001,000
0
55,489,400
0
55,539,900

55,539,900

55,489,400

58,001,000

56,988,200

58,420,000

57,376,900

54,812,300

53,790,900

53,389,600

51,073,300

48,854,000

48,139,800

16,775,200

14,515,500

13,348,278

12,377,850

12,161,261

11,772,046

11,079,847

10,308,027

9,319,892

Common Stock

0
18,400
0
0
0
161,394
0
161,394
0
161,394
0
161,394
0
161,394
0
161,394
0
161,400
0
322,800
0
0
0
322,800
0
327,800
0
322,800
0
322,800
0
322,800
0
313,800
0
313,600
0
313,600
0
313,600
313,600
313,600
0
313,600

313,600

313,800

322,800

327,800

322,800

161,400

161,394

18,400

Retained Earnings Total Equity

Accumulated Other Comprehensive Income

-16,894,200

-13,628,200

-12,207,600

-10,781,300

-8,578,000

-7,285,200

-6,094,990

-4,624,103

-3,844,953

Capital Surplus

Treasury Stock

Other Stockholders Equity

0
10,512,350
0
0
0
11,388,747
0
10,918,453
0
13,494,226
0
11,999,867
0
14,449,587
0
13,186,884
0
16,447,500
0
16,452,400
0
58,444,400
0
48,531,200
0
60,930,700
0
53,066,800
0
63,098,800
0
54,489,500
0
68,588,700
0
58,106,400
0
53,167,700
0
57,687,400
3,556,900
55,175,800
0
55,226,300

55,226,300

55,175,800

3,556,900

57,687,400

53,167,700

58,106,400

68,588,700

54,489,500

63,098,800

53,066,800

60,930,700

48,531,200

58,444,400

16,452,400

16,447,500

13,186,884

14,449,587

11,999,867

13,494,226

10,918,453

11,388,747

10,512,350

Balance Sheet

Currency in INR. All numbers in thousands.

	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31	2009-03-31	2008-03-31	2007-03-31	2006-03-31
Accounts Payable	1,933,700	1,630,200	2,835,200	1,945,700	1,859,100	856,400	869,700	1,514,354	928,665	1,055,503	1,657,874	1,739,825	-	-	-	-	-
Accumulated Other Comprehensive Income	-	-	-16,894,200	-13,628,200	-12,207,600	-10,781,300	-8,578,000	-7,285,200	-6,094,990	-4,624,103	-3,844,953	-2,940,492	-2,196,058	-1,728,121	-1,024,051	-677,513	-423,629
Capital Lease Obligations	4,091,000	4,229,600	3,012,800	540,200	524,500	379,400	-	-	-	-	-	-	-	-	-	-	-
Capital Stock	313,600	313,600	313,800	322,800	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Surpluse	47,387,600	47,387,600	47,410,700	47,777,200	47,777,200	0	-	-	-	-	-	-	-	-	-	-	-
Cash	1,102,400	2,435,400	1,219,400	763,200	655,200	586,100	561,400	243,162	307,171	171,382	240,409	425,056	454,518	451,575	370,976	355,472	1,351,769
Cash And Equivalents	500	0	-	0	15,900	15,800	-	-	-	-	-	-	-	-	-	-	-
Cash And Short Term Investments	4,973,400	4,312,000	2,566,900	1,234,400	1,878,400	769,500	561,400	375,162	307,171	171,382	240,409	2,104,850	454,518	451,575	370,976	355,472	1,351,769
Common Stock	313,600	313,600	313,800	322,800	327,800	0	161,400	161,394	161,394	161,394	18,400	161,394	161,394	161,394	159,368	144,426	137,335
Common Stock Shares Outstanding	156,609	156,793	160,998	161,394	161,394	161,394	161,394	161,394	161,394	161,394	161,394	161,394	162,666	162,666	162,666	162,661	162,661
Good Will	36,456,800	35,810,100	36,847,100	34,702,900	35,329,500	34,551,300	2,531,800	2,313,617	2,434,037	2,083,299	122,966	1,767,664	76,682	82,490	161,775	-	-
Intangible Assets	1,150,900	1,566,500	1,293,400	1,209,600	561,200	601,200	381,900	251,032	39,886	188,834	2,112,718	391,899	-	-	-	-	-
Inventory	6,451,200	5,156,500	6,068,700	5,486,200	4,845,600	4,265,800	4,831,100	4,482,604	4,232,554	3,382,697	2,670,624	2,702,176	2,423,454	3,039,640	3,047,316	2,977,802	1,082,230
Liabilities And Stockholders Equity	86,374,500	83,246,000	82,224,200	73,284,600	71,764,800	65,934,300	29,800,900	28,089,357	25,541,994	22,911,117	22,586,762	20,822,853	17,923,267	16,891,596	14,935,972	11,608,630	5,955,804
Long Term Debt	7,619,600	5,039,400	2,413,000	3,290,700	4,901,900	4,332,300	89,829	102,583	94,112	-	-	-	-	-	-	-	-
Long Term Debt Total	11,101,600	8,690,800	4,772,600	3,624,100	5,249,800	4,601,200	-	-	-	-	-	-	-	-	-	-	-
Long Term Investments	-	-	-	1,476,200	1,060,400	400,700	-	-	-	-	-	-	-	-	-	-	-
Net Debt	17,196,500	13,453,100	12,355,000	9,658,600	10,293,000	8,910,900	8,866,700	9,083,748	8,494,011	8,719,506	7,215,786	8,263,764	7,275,682	6,772,448	6,208,793	5,254,016	1,903,057
Net Invested Capital	69,697,300	67,452,300	67,938,500	63,672,500	61,497,000	-	-	-	-	-	-	-	-	-	-	-	-
Net Receivables	5,208,800	4,145,700	6,343,900	4,976,200	5,441,300	5,297,400	-	-	-	-	-	-	-	-	-	-	-
Net Tangible Assets	17,881,700	19,611,600	19,010,000	17,878,300	15,182,500	12,987,400	3,280	-5,642	-676	-	-	-	-	-	-	-	-
Net Working Capital	4,189,300	4,138,400	2,360,400	3,552,700	3,684,400	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Assets Total	67,987,300	66,619,600	64,174,500	57,748,900	56,303,300	52,603,800	18,786,900	17,954,100	17,937,341	16,178,086	16,348,035	14,279,008	12,043,197	10,041,336	8,348,978	6,184,456	2,209,638
Non Current Liabilities Other	1,529,100	51,400	-	-	200	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Liabilities Total	16,687,200	13,769,800	9,158,000	7,510,700	8,914,400	7,857,800	5,768,400	4,663,648	5,113,223	5,794,249	6,635,986	9,039,947	8,207,500	7,563,585	6,728,958	5,718,414	3,254,826
Non Currrent Assets Other	5,753,300	6,038,000	5,532,800	3,990,000	4,277,300	2,393,600	2,483,300	2,009,183	2,097,152	1,475,732	1,834,445	1,679,794	-1,819,385	-266,104	55,288	983,615	-192,709
Other Assets	2,192,500	4,263,800	4,249,500	3,596,500	3,128,800	3,278,200	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	6,962,600	7,157,900	9,414,100	8,815,100	8,737,500	8,295,200	5,625,400	5,277,491	3,064,928	3,178,952	3,327,694	1,736,819	3,002,098	3,359,045	3,168,702	2,090,900	1,312,167
Other Current Liab	5,055,400	3,518,000	3,929,700	2,805,100	3,576,700	3,521,500	3,408,600	3,508,478	2,724,966	1,553,410	2,637,331	1,251,514	1,873,156	2,284,097	2,472,277	2,706,915	815,765
Other Liab	5,585,600	5,079,000	4,385,400	3,886,600	3,664,500	3,256,700	-	-	-	-	-	-	-	-	-	-	-
Other Stockholder Equity	55,175,800	53,167,700	68,588,700	63,098,800	60,930,700	58,444,400	16,447,500	14,449,587	13,494,226	11,388,747	10,512,350	2,956,012	7,384,830	6,366,360	5,203,165	2,791,103	1,077,789
Property Plant And Equipment Net	27,868,800	24,414,600	20,929,800	16,761,900	16,223,400	14,648,800	13,389,900	13,262,816	13,366,266	12,430,221	12,277,906	12,076,839	13,760,647	10,205,331	8,131,915	5,200,841	2,401,850
Property Plant Equipment	27,868,800	24,414,600	20,929,600	16,763,600	16,223,300	14,648,900	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	4,231,300	3,506,900	5,368,600	3,997,500	2,022,400	476,700	6,484,600	5,052,069	4,211,416	3,381,989	2,634,095	8,614,653	2,492,445	2,244,281	1,396,255	925,285	1,093,718
Short Long Term Debt	6,588,300	5,424,700	8,148,600	6,590,900	5,518,100	4,785,400	89,829	103,096	121,241	-	-	-	-	-	-	-	-
Short Long Term Debt Total	18,298,900	15,888,500	13,574,400	10,421,800	10,948,200	9,497,000	9,428,100	9,326,910	8,801,182	8,890,888	7,456,195	8,688,820	7,730,200	7,224,023	6,579,769	5,609,488	3,254,826
Short Term Debt	7,197,300	7,197,700	8,801,800	6,797,700	5,698,500	4,895,900	5,238,700	6,025,027	5,003,094	4,199,928	2,335,679	-	-	-	-	-	-
Short Term Investments	3,871,000	1,876,600	1,347,500	471,200	1,223,200	183,400	-	132,000	-	-	-	1,679,794	-	-	-	-	-
Total Assets	86,374,500	83,246,000	82,224,200	73,284,600	71,764,800	65,934,300	29,804,800	28,089,357	25,541,994	22,911,117	22,586,762	20,822,853	17,923,267	16,891,596	14,935,972	11,608,630	5,955,804
Total Current Assets	18,387,200	16,626,400	18,049,700	15,535,700	15,461,500	13,330,500	11,017,900	10,135,257	7,604,653	6,733,031	6,238,727	6,543,845	5,880,070	6,850,260	6,586,994	5,424,174	3,746,166
Total Current Liabilities	14,197,900	12,488,000	15,689,300	11,983,000	11,777,100	9,936,700	9,517,000	11,047,859	8,656,725	6,808,841	6,630,884	2,991,339	1,873,156	2,284,097	2,472,277	2,706,915	815,765
Total Liab	30,885,100	26,257,800	24,847,300	19,493,700	20,691,500	17,794,500	15,285,400	15,711,507	13,769,948	12,603,090	13,266,870	12,031,286	10,080,656	9,847,682	9,201,235	8,425,329	4,070,591
Total Stockholder Equity	55,489,400	56,988,200	57,376,900	53,790,900	51,073,300	48,139,800	14,515,500	12,377,850	11,772,046	10,308,027	9,319,892	8,791,567	7,842,611	7,043,914	5,734,737	3,183,301	1,885,213

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31
Accounts Payable	1,955,000	-	1,933,700	1,928,900	1,590,300	-	1,630,200	-	1,794,300	-	2,835,200	-	2,076,400	-	1,945,700	-	1,326,700	-	1,859,100	-	707,500	-	856,400	-	881,500	-	869,700	-	828,406	-	1,514,354	-	746,753	-	928,665	-	1,016,523	-	1,055,503	-	-	-	1,657,874	-
Accumulated Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-16,894,200	-	-	-	-13,628,200	-	-	-	-12,207,600	-	-	-	-10,781,300	-	-	-	-8,578,000	-	-	-	-7,285,200	-	-	-	-6,094,990	-	-	-	-4,624,103	-	-	-	-3,844,953	-
Capital Lease Obligations	-	-	4,091,000	-	4,178,500	-	4,229,600	-	2,884,100	-	3,012,800	-	1,667,500	-	540,200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Stock	-	-	313,600	-	313,600	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash	-	-	1,102,400	-	1,604,000	-	2,435,400	-	1,409,400	-	1,219,400	-	959,700	-	763,200	-	1,646,000	-	655,200	-	539,700	-	586,100	-	287,600	-	561,400	-	524,336	-	243,162	-	469,345	-	307,171	-	330,594	-	171,382	-	-	-	240,409	-
Cash And Equivalents	2,689,800	-	1,720,900	-	2,379,100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash And Short Term Investments	4,335,700	-	4,973,400	-	4,546,600	-	4,312,000	-	3,260,700	-	2,566,900	-	2,374,000	-	1,234,400	-	2,666,900	-	1,878,400	-	2,322,000	-	769,500	-	3,891,300	-	561,400	-	656,336	-	375,162	-	469,345	-	307,171	-	330,594	-	171,382	-	-	-	240,409	-
Common Stock	313,600	-	313,600	313,600	313,600	-	313,600	-	313,600	-	313,800	-	322,800	-	322,800	-	322,800	-	327,800	-	322,800	-	-	-	322,800	-	161,400	-	161,394	-	161,394	-	161,394	-	161,394	-	161,394	-	161,394	-	-	-	18,400	-
Common Stock Shares Outstanding	156,783	154,231	156,549	156,549	157,606	157,059	157,549	157,549	157,021	156,423	156,423	161,029	161,412	161,080	156,423	161,541	161,209	161,138	161,325	161,538	161,333	160,741	161,472	161,401	161,298	161,383	161,788	161,287	161,515	161,360	156,423	161,301	161,527	161,452	156,423	161,227	161,366	161,616	156,423	161,684	161,207	161,282	156,423	161,554
Good Will	35,827,500	-	36,456,800	-	36,187,600	-	35,810,100	-	36,905,500	-	36,847,100	-	34,640,700	-	34,702,900	-	36,607,400	-	35,329,500	-	34,069,000	-	34,551,300	-	2,531,800	-	2,531,800	-	134,811	-	2,313,617	-	122,954	-	2,434,037	-	122,954	-	2,083,299	-	-	-	122,966	-
Intangible Assets	1,106,800	-	1,150,900	-	1,683,100	-	1,566,500	-	1,341,100	-	1,293,400	-	1,193,300	-	1,209,600	-	546,800	-	561,200	-	682,100	-	601,200	-	160,900	-	381,900	-	-	-	251,032	-	-	-	39,886	-	-	-	188,834	-	-	-	2,112,718	-
Inventory	7,492,700	-	6,451,200	6,451,200	5,829,300	-	5,156,500	-	5,900,000	-	6,068,700	-	6,213,000	-	5,486,200	-	5,208,400	-	4,845,600	-	4,922,200	-	4,265,800	-	4,947,600	-	4,831,100	-	4,934,176	-	4,482,604	-	4,943,747	-	4,232,554	-	4,129,049	-	3,382,697	-	-	-	2,670,624	-
Liabilities And Stockholders Equity	88,264,400	-	86,374,500	-	85,354,300	-	83,246,000	-	82,154,200	-	82,224,200	-	77,745,900	-	73,284,600	-	76,314,100	-	71,764,800	-	67,250,300	-	65,934,300	-	30,861,700	-	29,800,900	-	28,417,413	-	28,089,357	-	26,400,753	-	25,541,994	-	25,429,222	-	22,911,117	-	-	-	22,586,762	-
Long Term Debt	9,210,000	-	7,619,600	-	5,222,800	-	5,039,400	-	2,441,100	-	2,413,000	-	3,647,200	-	3,624,100	-	5,190,600	-	4,901,900	-	5,770,400	-	4,601,200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Total	12,420,300	-	11,101,600	-	8,810,300	-	8,690,800	-	4,666,200	-	4,772,600	-	4,950,200	-	3,624,100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Investments	-	-	-	-	-	-	-	-	-	-	-	-	1,345,400	-	1,476,200	-	1,843,700	-	1,036,800	-	391,700	-	423,600	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Debt	-	-	17,196,500	-	13,910,400	-	13,453,100	-	10,596,700	-	12,355,000	-	10,416,300	-	9,658,600	-	9,723,800	-	10,293,000	-	8,970,300	-	8,910,900	-	7,427,900	-	8,866,700	-	7,217,421	-	9,083,748	-	6,733,668	-	8,494,011	-	8,303,195	-	8,719,506	-	-	-	7,215,786	-
Net Invested Capital	-	-	69,697,300	-	69,336,900	-	67,452,300	-	67,542,000	-	67,938,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Receivables	5,338,200	-	5,208,800	5,208,800	3,581,400	-	4,145,700	-	4,730,500	-	6,343,900	-	4,293,900	-	4,453,000	-	5,870,400	-	5,821,800	-	3,986,100	-	3,967,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Tangible Assets	18,605,600	17,881,700	17,881,700	17,881,700	20,130,300	19,611,600	19,611,600	20,179,400	20,179,400	19,236,200	19,236,200	18,978,300	18,978,300	17,878,300	17,878,300	16,235,400	16,235,400	15,182,500	15,182,500	14,102,900	14,102,900	12,987,200	12,987,200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Working Capital	-	-	4,189,300	-	3,192,200	-	4,138,400	-	2,148,800	-	2,360,400	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Assets Total	-	-	67,987,300	-	68,696,500	-	66,619,600	-	65,115,300	-	64,174,500	-	61,199,800	-	57,748,900	-	59,207,800	-	56,303,300	-	52,626,600	-	52,603,800	-	20,233,100	-	18,786,900	-	18,241,023	-	17,954,100	-	17,416,121	-	17,937,341	-	17,695,283	-	16,178,086	-	-	-	16,348,035	-
Non Current Liabilities Other	-	-	1,529,100	-	50,300	-	51,400	-	6,000	-	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Liabilities Total	-	-	16,687,200	-	13,887,700	-	13,769,800	-	8,844,100	-	9,158,000	-	8,880,100	-	7,510,700	-	9,200,200	-	8,914,400	-	9,272,500	-	7,857,800	-	4,704,800	-	5,768,400	-	5,808,769	-	4,663,648	-	5,050,636	-	5,113,223	-	5,798,774	-	5,794,249	-	-	-	6,635,986	-
Non Currrent Assets Other	-	-	5,753,300	-	7,044,500	-	6,038,000	-	6,106,200	-	5,532,800	-	5,666,400	-	3,990,000	-	4,202,100	-	4,277,300	-	3,931,300	-	2,393,600	-	5,837,600	-	2,483,300	-	2,190,273	-	2,009,183	-	1,885,259	-	2,097,152	-	1,493,869	-	1,475,732	-	-	-	1,834,445	-
Other Assets	2,294,500	-	2,192,500	2,192,500	4,259,800	-	4,263,800	-	4,314,500	-	4,215,600	-	2,992,600	-	2,161,100	-	3,241,900	-	3,152,400	-	2,371,500	-	3,101,800	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2,076,700	-	6,962,600	2,699,500	6,281,900	-	7,157,900	-	7,878,200	-	9,414,100	-	7,959,200	-	8,815,100	-	9,231,000	-	8,737,500	-	7,379,500	-	8,295,200	-	1,789,700	-	5,625,400	-	4,585,878	-	5,277,491	-	3,571,540	-	3,064,928	-	3,274,316	-	3,178,952	-	-	-	3,327,694	-
Other Current Liab	6,280,900	-	5,055,400	3,723,600	5,171,200	-	3,518,000	-	5,598,200	-	3,929,700	-	5,177,200	-	2,805,100	-	5,607,800	-	3,576,700	-	4,225,300	-	3,521,500	-	4,035,700	-	3,408,600	-	4,993,877	-	3,508,478	-	4,997,078	-	2,724,966	-	3,491,900	-	1,553,410	-	-	-	2,637,331	-
Other Liab	4,105,900	-	5,585,600	5,585,600	5,077,400	-	5,079,000	-	4,171,900	-	4,385,400	-	3,929,800	-	3,886,600	-	4,009,600	-	3,664,500	-	3,502,000	-	3,256,600	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Stockholder Equity	55,226,300	-	55,175,800	3,556,900	57,687,400	-	53,167,700	-	58,106,400	-	68,588,700	-	54,489,500	-	63,098,800	-	53,066,800	-	60,930,700	-	48,531,200	-	58,444,400	-	16,452,400	-	16,447,500	-	13,186,884	-	14,449,587	-	11,999,867	-	13,494,226	-	10,918,453	-	11,388,747	-	-	-	10,512,350	-
Property Plant And Equipment Net	-	-	27,868,800	-	26,001,700	-	24,414,600	-	21,227,800	-	20,929,800	-	19,692,000	-	16,761,900	-	16,968,000	-	16,223,400	-	15,112,300	-	14,648,800	-	15,032,300	-	13,389,900	-	15,813,613	-	13,262,816	-	15,407,908	-	13,366,266	-	16,078,460	-	12,430,221	-	-	-	12,277,906	-
Property Plant Equipment	29,585,800	-	27,868,800	27,868,800	26,001,700	-	24,414,600	-	21,227,800	-	20,929,600	-	19,692,000	-	16,763,600	-	16,968,000	-	16,223,300	-	15,112,300	-	14,648,900	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	55,226,300	-	4,231,300	4,231,300	57,687,400	-	3,506,900	-	58,112,400	-	5,368,600	-	54,489,600	-	3,997,500	-	-	-	2,022,400	-	-	-	476,700	-	-	-	6,484,600	-	-	-	5,052,069	-	-	-	4,211,416	-	-	-	3,381,989	-	-	-	2,634,095	-
Short Long Term Debt	-	-	6,588,300	-	6,113,100	-	5,424,700	-	6,680,900	-	8,148,600	-	6,061,300	-	6,590,900	-	-	9,182,900	1,585,000	9,510,000	9,510,000	8,940,400	8,940,400	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Long Term Debt Total	-	-	18,298,900	-	15,514,400	-	15,888,500	-	12,006,100	-	13,574,400	-	11,376,000	-	10,421,800	-	11,369,800	-	10,948,200	-	9,510,000	-	9,497,000	-	7,715,500	-	9,428,100	-	7,741,757	-	9,326,910	-	7,203,013	-	8,801,182	-	8,633,789	-	8,890,888	-	-	-	7,456,195	-
Short Term Debt	0	-	7,197,300	-	6,704,100	-	7,197,700	-	7,339,900	-	8,801,800	-	6,425,800	-	6,797,700	-	6,179,200	9,182,900	5,698,500	9,510,000	3,739,600	8,940,400	4,895,900	-	4,464,500	-	5,238,700	-	3,438,083	-	6,025,027	-	3,445,025	-	5,003,094	-	4,042,178	-	4,199,928	-	-	-	2,335,679	-
Short Term Investments	1,645,900	-	3,871,000	-	2,942,600	-	1,876,600	-	1,851,300	-	1,347,500	-	1,414,300	-	471,200	-	1,020,900	-	1,223,200	-	1,782,300	-	183,400	-	3,603,700	-	-	-	132,000	-	132,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	88,264,400	-	86,374,500	-	85,354,300	-	83,246,000	-	82,154,200	-	82,224,200	-	77,746,000	-	73,284,600	-	76,314,100	-	71,764,800	-	67,250,300	-	65,934,300	-	30,861,700	-	29,804,800	-	28,417,413	-	28,089,357	-	26,400,753	-	25,541,994	-	25,429,242	-	22,911,117	-	-	-	22,586,762	-
Total Current Assets	19,120,600	-	18,387,200	18,387,200	16,657,800	-	16,626,400	-	17,038,900	-	18,049,700	-	16,546,200	-	15,535,700	-	17,106,300	-	15,461,500	-	14,623,700	-	13,330,500	-	10,628,600	-	11,017,900	-	10,176,390	-	10,135,257	-	8,984,632	-	7,604,653	-	7,733,959	-	6,733,031	-	-	-	6,238,727	-
Total Current Liabilities	16,198,300	-	14,197,900	14,197,900	13,465,600	-	12,488,000	-	14,890,100	-	15,689,300	-	14,053,500	-	11,983,000	-	13,724,300	-	11,777,100	-	9,123,800	-	9,936,700	-	9,381,700	-	9,517,000	-	9,260,366	-	11,047,859	-	9,188,856	-	8,656,725	-	8,550,601	-	6,808,841	-	-	-	6,630,884	-
Total Liab	32,724,500	-	30,885,100	-	27,353,300	-	26,257,800	-	23,734,200	-	24,847,300	-	22,933,600	-	19,493,700	-	22,924,500	-	20,691,500	-	18,396,300	-	17,794,500	-	14,086,500	-	15,285,400	-	15,069,135	-	15,711,507	-	14,239,492	-	13,769,948	-	14,349,375	-	12,603,090	-	-	-	13,266,870	-
Total Stockholder Equity	55,539,900	-	55,489,400	-	58,001,000	-	56,988,200	-	58,420,000	-	57,376,900	54,812,300	54,812,300	53,790,900	53,790,900	53,389,600	53,389,600	51,073,300	51,073,300	48,854,000	48,854,000	48,139,800	48,139,800	-	16,775,200	-	14,515,500	-	13,348,278	-	12,377,850	-	12,161,261	-	11,772,046	-	11,079,847	-	10,308,027	-	-	-	9,319,892	-

Cash Flow

Currency in INR. All numbers in thousands.

	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31	2009-03-31	2008-03-31	2007-03-31	2006-03-31
Begin Period Cash Flow	2,435,400	1,219,400	763,200	655,200	586,100	560,400	243,900	307,808	171,382	240,409	425,056	454,518	451,575	370,976	355,472	1,351,769	91,681
Capital Expenditures	4,638,000	3,660,300	4,085,600	3,081,100	2,164,500	1,479,600	1,238,700	1,554,289	2,992,004	1,093,643	949,128	2,433,196	3,058,359	1,746,516	2,699,918	4,177,520	858,356
Change In Cash	-1,333,000	1,216,000	456,200	108,000	69,100	238,100	316,500	-63,882	136,426	-30,389	-184,647	-29,462	2,943	80,599	15,504	-996,297	1,260,088
Change In Working Capital	798,200	3,171,200	1,073,500	-1,744,300	-2,062,600	-294,300	-834,900	37,676	-34,258	-1,445,689	63,933	512,767	466,122	-105,590	-1,385,657	-834,844	-456,053
Change To Account Receivables	-593,600	2,218,700	-1,255,600	-9,000	-1,588,500	-1,332,200	-1,332,200	-1,332,200	-1,332,200	-	-	-	-	-	-	-	-
Change To Inventory	-1,433,000	909,100	-582,500	-640,600	-579,800	565,300	-348,500	-250,050	-849,857	-712,073	31,552	-278,722	616,186	7,675	-69,514	-1,895,572	-267,880
Change To Liabilities	2,357,100	-814,500	1,901,200	86,500	1,013,200	-13,300	1,856	-1,979	72	-	-	-	-	-	-	-	-
Change To Netincome	378,800	1,419,500	999,900	942,500	1,551,800	616,000	-3,148	-4,447	-8,070	-	-	-	-	-	-	-	-
Change To Operating Activities	467,700	857,900	1,010,400	-1,181,600	-907,500	485,900	7,777	-1,662	-24,559	-	-	-	-	-	-	-	-
Depreciation	3,075,900	3,079,400	2,828,700	2,403,800	2,114,200	2,135,000	1,090,600	1,507,111	1,085,623	838,382	765,247	687,631	594,160	629,130	471,853	266,239	122,308
Dividends Paid	-	-	-32,300	32,300	32,300	193,700	322,700	96,837	96,837	96,837	96,837	96,837	96,837	80,697	76,255	48,156	34,334
End Period Cash Flow	1,102,400	2,435,400	1,219,400	763,200	655,200	586,100	560,400	243,926	307,808	210,020	240,409	425,056	454,518	451,575	370,976	355,472	1,351,769
Free Cash Flow	-1,089,500	1,474,000	1,765,800	-260,700	99,900	1,546,900	1,547,700	1,303,664	453,019	279,550	586,635	-378,361	-36,256	-428,874	-2,205,565	-3,750,203	-704,333
Investments	-1,711,500	-91,800	-276,700	678,400	-1,483,900	26,300	26,300	26,300	3,000	-	-	-	-	-	-	-	-
Net Borrowings	1,901,600	441,200	32,400	-450,000	1,264,700	-649,100	-12,754	8,470	-1,462	-	-	-	-	-	-	-	-
Net Income	180,100	-1,651,300	1,803,000	2,103,300	1,545,700	1,454,300	1,711,100	1,198,090	1,092,722	1,002,938	567,585	813,443	1,173,750	1,461,911	1,197,068	917,090	508,445
Other Cashflows From Financing Activities	2,970,400	1,782,400	1,714,000	1,223,100	1,747,000	3,229,400	1,765,100	-631,927	250,194	170,822	-82,597	353,190	49,723	770,285	2,129,623	2,800,220	1,957,526
Other Cashflows From Investing Activities	52,900	498,400	-12,700	-5,100	386,300	115,200	3,148	4,453	8,194	-	-	-	-	-	-	-	-
Other Non Cash Items	-505,700	535,000	146,200	57,600	667,100	-268,500	819,600	115,076	1,300,936	977,562	138,998	40,994	788,071	-667,809	211,089	78,832	-20,677
Sale Purchase Of Stock	0	-23,100	-366,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Cash From Financing Activities	1,303,700	-110,400	-977,800	-1,022,300	776,200	-1,370,800	-941,100	-1,425,162	-740,616	-501,494	-680,397	254,541	-70,016	500,201	2,053,368	2,752,064	1,923,192
Total Cash From Operating Activities	3,548,500	5,134,300	5,851,400	2,820,400	2,264,400	3,026,500	2,786,400	2,857,953	3,445,023	1,373,193	1,535,763	2,054,835	3,022,103	1,317,642	494,353	427,317	154,023
Total Cashflows From Investing Activities	-6,185,300	-3,807,900	-4,417,400	-1,690,200	-2,971,600	-1,424,100	3,148	4,453	8,194	-	-	-	-	-	-	-	-

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31
Begin Period Cash Flow	-	-	-	-	-	-	-	304,850	190,800	190,800	190,800	190,800	190,800	163,800	163,800	163,800	163,800	146,525	146,525	146,525	146,525	146,525	146,525	140,100	60,975	60,975	60,975	76,952	76,952	76,952	76,952	42,846	42,846	42,846	42,846	60,102	60,102	60,102	60,102	106,264	106,264	106,264	106,264	113,630	113,630	113,630	113,630	112,894	112,894	112,894	112,894	92,744	92,744	92,744	92,744	88,868	88,868	88,868	88,868	337,942	337,942	337,942	337,942	22,920	22,920	22,920	22,920
Capital Expenditures	3,190,700	0	1,137,000	1,137,000	1,137,000	1,137,000	3,660,300	0	1,021,400	1,021,400	1,021,400	1,021,400	2,233,500	770,275	770,275	770,275	0	541,125	541,125	541,125	0	369,900	369,900	369,900	309,675	309,675	309,675	388,572	388,572	388,572	388,572	748,001	748,001	748,001	748,001	273,411	273,411	273,411	273,411	237,282	237,282	237,282	237,282	608,299	608,299	608,299	608,299	764,590	764,590	764,590	764,590	436,629	436,629	436,629	436,629	674,980	674,980	674,980	674,980	1,044,380	1,044,380	1,044,380	1,044,380	214,589	214,589	214,589	214,589
Change In Cash	583,300	-	-250,800	-250,800	-250,800	-250,800	1,216,000	-	114,050	114,050	114,050	114,050	196,500	27,000	27,000	27,000	-	17,275	17,275	17,275	-	-	-	-	79,125	79,125	79,125	-15,971	-15,971	-15,971	-15,971	34,107	34,107	34,107	34,107	-7,597	-7,597	-7,597	-7,597	-46,162	-46,162	-46,162	-46,162	-7,366	-7,366	-7,366	-7,366	736	736	736	736	20,150	20,150	20,150	20,150	3,876	3,876	3,876	3,876	-249,074	-249,074	-249,074	-249,074	315,022	315,022	315,022	315,022
Change In Working Capital	-689,000	-	234,800	-	470,500	-	2,659,200	-	268,375	268,375	268,375	268,375	-	-436,075	-436,075	-436,075	-	-515,650	-515,650	-515,650	-	-73,575	-73,575	-73,575	-208,725	-208,725	-208,725	9,419	9,419	9,419	9,419	-8,565	-8,565	-8,565	-8,565	-361,422	-361,422	-361,422	-361,422	15,983	15,983	15,983	15,983	128,192	128,192	128,192	128,192	116,531	116,531	116,531	116,531	-26,398	-26,398	-26,398	-26,398	-346,414	-346,414	-346,414	-346,414	-208,711	-208,711	-208,711	-208,711	-114,013	-114,013	-114,013	-114,013
Change To Account Receivables	-	-	-652,100	-652,100	-652,100	-652,100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Inventory	-	-	-399,600	-399,600	-399,600	-399,600	-	-	-145,625	-145,625	-145,625	-145,625	-	-160,150	-160,150	-160,150	-	-144,950	-144,950	-144,950	-	141,325	141,325	141,325	-87,125	-87,125	-87,125	-62,513	-62,513	-62,513	-62,513	-212,464	-212,464	-212,464	-212,464	-178,018	-178,018	-178,018	-178,018	7,888	7,888	7,888	7,888	-69,681	-69,681	-69,681	-69,681	154,047	154,047	154,047	154,047	1,919	1,919	1,919	1,919	-17,379	-17,379	-17,379	-17,379	-473,893	-473,893	-473,893	-473,893	-66,970	-66,970	-66,970	-66,970
Change To Liabilities	0	0	1,268,100	1,268,100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Netincome	-	-	291,400	291,400	291,400	-150,850	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Operating Activities	-	-	-274,650	-274,650	-274,650	-274,650	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation	1,483,800	-	320,550	320,550	320,550	794,150	3,079,400	-	707,175	707,175	707,175	707,175	1,372,600	600,950	600,950	600,950	-	528,550	528,550	528,550	-	533,750	533,750	533,750	272,650	272,650	272,650	376,778	376,778	376,778	376,778	271,406	271,406	271,406	271,406	209,596	209,596	209,596	209,596	191,312	191,312	191,312	191,312	171,908	171,908	171,908	171,908	148,540	148,540	148,540	148,540	157,283	157,283	157,283	157,283	117,963	117,963	117,963	117,963	66,560	66,560	66,560	66,560	30,577	30,577	30,577	30,577
Dividends Paid	-	-	-	-	-	-	-	-	-8,075	-8,075	-8,075	-8,075	32,300	-	-	-	-	-	-	-	-	48,425	48,425	48,425	80,675	80,675	80,675	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	24,209	20,174	20,174	20,174	20,174	19,064	19,064	19,064	19,064	12,039	12,039	12,039	12,039	8,584	8,584	8,584	8,584
End Period Cash Flow	-	-	-	-	-	-	-	-	304,850	304,850	304,850	304,850	190,800	190,800	190,800	190,800	163,800	163,800	163,800	163,800	146,525	146,525	146,525	146,525	140,100	140,100	140,100	60,982	60,982	60,982	60,982	76,952	76,952	76,952	76,952	52,505	52,505	52,505	52,505	60,102	60,102	60,102	60,102	106,264	106,264	106,264	106,264	113,630	113,630	113,630	113,630	112,894	112,894	112,894	112,894	92,744	92,744	92,744	92,744	88,868	88,868	88,868	88,868	337,942	337,942	337,942	337,942
Free Cash Flow	-	-	-	-	-	-	-	-	441,450	441,450	441,450	441,450	-	-65,175	-65,175	-65,175	-	24,975	24,975	24,975	-	386,725	386,725	386,725	386,925	386,925	386,925	325,916	325,916	325,916	325,916	113,255	113,255	113,255	113,255	69,888	69,888	69,888	69,888	146,659	146,659	146,659	146,659	-94,590	-94,590	-94,590	-94,590	-9,064	-9,064	-9,064	-9,064	-107,219	-107,219	-107,219	-107,219	-551,391	-551,391	-551,391	-551,391	-937,551	-937,551	-937,551	-937,551	-176,083	-176,083	-176,083	-176,083
Investments	-	-	-763,750	-763,750	-763,750	-763,750	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Borrowings	-	-	1,204,650	1,204,650	1,204,650	1,204,650	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-100,500	40,100	-46,000	-46,000	111,900	160,200	-1,350,400	-160,700	73,800	-214,300	719,800	555,200	1,115,900	343,100	753,400	771,975	440,100	396,400	511,400	576,975	484,000	130,200	427,900	540,200	455,100	289,600	583,400	365,024	377,582	386,056	398,118	333,553	238,142	225,859	391,006	422,778	292,525	185,761	363,211	265,992	387,076	312,478	219,780	230,266	230,266	230,266	230,266	331,322	331,322	331,322	331,322	393,639	393,639	393,639	393,639	307,113	307,113	307,113	307,113	239,918	239,918	239,918	239,918	136,290	136,290	136,290	136,290
Other Cashflows From Financing Activities	-391,700	-	-175,850	-175,850	-175,850	-175,850	-528,500	-	25	25	25	25	-283,400	25	25	25	-	-25	-25	-25	-	-	-	-	25	25	25	-4,114	-4,114	-4,114	-4,114	-3,927	-3,927	-3,927	-3,927	-3,927	-3,927	-3,927	-3,927	-4,504	-4,504	-4,504	-4,504	-12,647	-12,647	-12,647	-12,647	10,404	10,404	10,404	10,404	953	953	953	953	48,425	48,425	48,425	48,425	-7,689	-7,689	-7,689	-7,689	12,230	12,230	12,230	12,230
Other Cashflows From Investing Activities	1,096,000	-	18,950	18,950	18,950	18,950	-147,600	-	-256,800	-	-331,900	-	-120,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non Cash Items	-	-	-	-	-	-	-	-	413,500	701,600	-232,500	-67,900	-	197,125	-213,175	-231,750	-	156,800	41,800	-23,775	-	166,250	-131,450	-243,750	177,575	343,075	49,275	-36,733	-49,291	-57,765	-69,826	264,862	360,273	372,556	207,409	72,347	202,600	309,364	131,915	-89,346	-210,430	-135,832	-43,134	-16,657	-16,657	-16,657	-16,657	159,133	159,133	159,133	159,133	-195,114	-195,114	-195,114	-195,114	44,927	44,927	44,927	44,927	9,063	9,063	9,063	9,063	-14,348	-14,348	-14,348	-14,348
Sale Purchase Of Stock	-	-	0	-	0	-	-23,100	-	-91,625	-91,625	-91,625	-91,625	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Cash From Financing Activities	1,674,100	-	1,028,800	1,028,800	1,028,800	1,028,800	-110,400	-	-188,100	-	-977,800	-	764,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Cash From Operating Activities	1,003,900	-	539,050	539,050	539,050	539,050	5,134,300	-	1,462,850	1,462,850	1,462,850	1,462,850	1,786,000	705,100	705,100	705,100	-	566,100	566,100	566,100	-	756,625	756,625	756,625	696,600	696,600	696,600	714,488	714,488	714,488	714,488	861,256	861,256	861,256	861,256	343,298	343,298	343,298	343,298	383,941	383,941	383,941	383,941	513,709	513,709	513,709	513,709	755,526	755,526	755,526	755,526	329,411	329,411	329,411	329,411	123,588	123,588	123,588	123,588	106,829	106,829	106,829	106,829	38,506	38,506	38,506	38,506
Total Cashflows From Investing Activities	-2,094,700	-	-1,818,700	-1,818,700	-1,818,700	-1,818,700	-3,807,900	-	-1,449,600	-	-4,417,500	-	-2,353,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Income Statement

Currency in INR. All numbers in thousands.

	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31	2009-03-31	2008-03-31	2007-03-31	2006-03-31
Cost Of Revenue	4,474,200	4,840,900	4,507,300	4,195,200	3,520,500	3,375,700	3,458,800	5,395,553	3,780,943	3,800,980	3,845,301	4,494,830	3,573,643	4,034,256	3,506,120	2,535,610	1,520,378
Depreciation And Amortization	3,075,900	3,079,400	2,828,700	2,403,800	2,114,200	2,135,000	1,090,600	1,507,111	1,085,623	838,382	765,247	687,631	594,160	629,130	471,853	266,239	122,308
Ebit	525,600	-260,000	2,708,500	3,507,700	2,733,500	2,545,400	3,017,600	2,383,389	2,271,036	2,180,878	1,608,554	921,063	1,323,275	1,565,824	1,207,947	946,649	538,664
Ebitda	3,601,500	2,819,400	5,537,200	5,911,500	4,847,700	4,680,400	4,108,200	3,890,500	3,356,659	3,019,260	2,373,801	1,608,694	1,917,435	2,194,954	1,679,800	1,212,888	660,972
Gross Profit	16,932,700	14,279,400	15,928,700	16,390,700	13,425,900	13,761,200	12,501,700	10,356,499	10,071,539	8,921,198	7,395,816	5,413,610	5,579,931	6,589,322	4,524,642	3,250,110	1,254,020
Income Before Tax	-42,500	-650,300	2,220,800	3,087,900	2,307,900	2,160,800	2,333,600	1,592,471	1,564,023	1,452,842	879,119	921,063	1,325,288	1,574,556	1,228,451	959,671	545,161
Income Tax Expense	-222,600	1,001,000	417,800	984,600	762,200	706,500	623,600	394,381	471,300	449,904	311,534	107,620	149,525	103,913	10,879	29,559	30,219
Interest Expense	568,100	390,300	487,700	419,800	425,600	384,600	682,900	790,918	707,014	728,036	729,435	0	0	0	0	0	0
Interest Income	568,100	476,100	410,200	537,800	451,200	261,800	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	180,100	-1,651,300	1,803,000	2,103,300	1,545,700	1,454,300	1,711,100	1,198,090	1,092,722	1,002,938	567,585	813,443	1,173,750	1,461,911	1,197,068	917,090	508,445
Net Income Applicable To Common Shares	180,100	-1,651,300	1,585,100	2,103,300	1,545,700	1,454,300	8,922	-4,966	-1,358	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	180,100	-1,651,300	1,803,000	2,103,300	1,545,700	1,454,300	8,922	-4,966	-1,358	-	-	-	-	-	-	-	-
Net Interest Income	-568,100	-476,100	-274,700	-292,500	-405,100	-348,800	-	-	-	-	-	-	-	-	-	-	-
Operating Income	237,800	-123,500	2,580,100	3,356,300	2,512,500	2,476,700	3,025,300	1,745,462	2,199,115	2,103,581	1,576,560	1,336,797	1,434,237	1,975,700	1,056,672	888,011	527,442
Other Operating Expenses	21,169,100	19,243,800	17,855,900	17,229,600	14,433,900	14,660,200	12,935,200	14,006,590	11,653,367	10,618,597	9,664,557	8,571,643	7,719,337	8,647,878	6,974,090	4,897,709	2,246,956
Reconciled Depreciation	3,075,900	3,079,400	2,828,700	2,403,800	2,114,200	-	-	-	-	-	-	-	-	-	-	-	-
Research Development	-	-	-	-	-	-	-	5,728	11,499	2,708	32,422	-	-	-	-	-	-
Selling And Marketing Expenses	-	219,400	57,800	51,400	12,700	522,100	74,700	147,698	133,425	129,393	185,437	-	-	-	-	-	-
Selling General Administrative	9,814,900	630,900	557,600	731,300	495,700	613,600	493,600	405,860	321,249	265,464	1,322,831	987,419	1,001,576	1,244,610	841,959	689,651	262,858
Tax Provision	-222,600	1,001,000	417,800	984,600	762,200	706,500	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	16,694,900	14,402,900	13,348,600	13,034,400	10,913,400	11,284,500	9,476,400	8,611,037	7,872,424	6,817,617	5,819,256	4,076,813	4,145,694	4,613,622	3,467,970	2,362,099	726,578
Total Other Income Expense Net	-280,300	-526,800	-359,300	-268,400	-204,600	-315,900	-691,700	-152,991	-635,092	-650,739	-697,441	-415,734	-108,949	-401,144	171,779	71,660	17,719
Total Revenue	21,406,900	19,120,300	20,436,000	20,585,900	16,946,400	17,136,900	15,960,500	15,752,052	13,852,482	12,722,178	11,241,117	9,908,440	9,153,574	10,623,578	8,030,762	5,785,720	2,774,398

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31
Cost Of Revenue	1,612,100	919,900	1,477,200	1,288,300	424,000	1,284,700	1,823,300	851,300	678,900	1,487,400	1,281,800	1,296,200	626,700	1,302,600	1,682,400	719,600	690,900	1,102,200	1,066,300	1,034,200	794,500	459,600	1,174,000	684,100	918,400	541,800	684,000	844,257	902,485	823,692	1,888,318	1,274,487	1,188,190	1,044,557	1,240,593	910,613	876,675	753,063	1,005,853	1,085,771	867,631	841,725	1,215,319	879,928
Depreciation And Amortization	-	750,800	838,800	749,500	740,500	747,100	767,600	790,800	707,175	707,175	707,175	720,800	700,000	600,950	600,950	576,900	575,000	528,550	528,550	549,600	545,700	533,750	533,750	292,500	308,900	272,650	272,650	270,973	376,778	376,778	376,778	254,626	271,406	271,406	271,406	265,696	209,596	209,596	209,596	207,127	191,312	191,312	191,312	191,139
Ebit	-9,700	188,800	-696,500	535,900	322,800	363,400	-130,700	-75,200	165,900	-219,300	663,700	621,200	823,800	599,900	1,035,200	884,200	860,800	727,600	861,600	808,600	874,400	251,800	930,100	682,100	925,500	807,100	595,400	845,649	729,873	826,146	669,425	562,437	647,947	493,483	541,060	399,359	711,722	618,889	566,049	476,800	469,292	668,737	738,754	308,746
Ebitda	-	939,600	142,300	1,285,400	1,063,300	1,110,500	636,900	715,600	873,075	487,875	1,370,875	1,342,000	1,523,800	1,200,850	1,636,150	1,461,100	1,435,800	1,256,150	1,390,150	1,358,200	1,420,100	785,550	1,463,850	974,600	1,234,400	1,079,750	868,050	1,116,622	1,106,651	1,202,924	1,046,203	817,063	919,353	764,889	812,466	665,055	921,318	828,485	775,645	683,927	660,604	860,049	930,066	499,885
Gross Profit	4,527,500	4,486,200	4,212,700	4,332,500	4,165,000	4,222,600	3,509,100	3,781,100	3,725,300	3,263,900	4,449,800	3,897,400	3,871,200	3,710,300	5,818,300	3,554,300	3,633,200	3,385,100	3,459,200	3,274,900	3,513,400	2,910,300	3,697,000	2,880,600	3,351,000	3,117,000	2,880,700	2,980,485	2,834,160	3,176,671	2,466,467	2,583,947	2,735,045	2,571,041	2,886,034	2,223,630	2,652,497	2,309,377	2,495,221	2,089,961	2,024,979	2,311,037	2,311,576	1,773,824
Income Before Tax	-122,900	-3,000	-852,900	384,800	185,900	239,700	-135,700	-218,800	39,700	-335,700	598,100	506,800	653,900	462,000	1,054,400	744,600	708,400	580,600	748,800	680,600	740,600	137,900	828,700	685,800	736,400	582,500	461,500	660,624	493,927	507,428	526,059	305,614	472,928	287,870	504,726	198,747	522,285	338,264	454,122	224,605	336,531	437,584	521,031	259,905
Income Tax Expense	-22,400	-43,100	-407,100	31,000	74,000	79,500	1,214,700	-58,100	-34,100	-121,500	-121,700	178,300	242,300	118,900	301,000	230,900	268,300	184,200	237,400	260,600	256,700	7,800	400,800	175,300	189,700	127,400	171,900	191,278	128,903	129,856	139,652	65,273	139,357	50,099	278,764	47,189	99,507	45,841	268,003	60,668	70,868	50,365	208,202	92,709
Interest Expense	-	191,800	156,400	151,100	136,900	123,700	5,000	143,600	126,200	116,500	65,600	114,400	169,900	137,900	19,200	139,600	152,400	147,000	112,800	128,000	133,700	113,800	101,400	-	189,000	224,600	133,900	185,025	235,946	318,708	143,717	256,825	175,037	205,242	36,437	200,617	189,437	280,523	112,285	252,023	132,432	231,296	218,074	48,829
Interest Income	201,700	191,800	156,400	151,100	136,900	123,700	90,700	143,600	126,200	115,500	197,400	114,400	169,900	137,900	126,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	0	0	0	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-100,500	40,100	-445,800	353,800	111,900	160,200	-1,350,400	-160,700	73,800	-214,300	719,800	328,500	411,600	343,100	753,400	513,700	440,100	396,400	511,400	420,000	484,000	130,200	427,900	506,800	546,800	455,100	289,600	469,346	365,024	377,582	386,056	240,339	333,553	238,142	225,859	151,553	422,778	292,525	185,761	164,109	265,992	387,076	312,478	167,208
Net Income Applicable To Common Shares	-100,500	40,100	-46,000	-46,000	111,900	160,200	-1,350,400	-160,700	73,800	-214,300	719,800	328,500	411,600	343,100	757,900	513,700	440,100	396,400	511,600	420,000	484,000	130,200	427,900	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	-	40,100	-445,800	353,800	111,900	160,200	-1,350,400	-160,700	73,800	-214,200	719,800	328,500	411,600	343,100	753,400	513,700	440,100	396,400	511,600	420,000	484,000	130,200	427,900	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Interest Income	-	-191,800	-156,400	-151,100	-136,900	-123,700	-90,800	-143,600	-126,200	-116,500	147,400	-114,400	-169,900	-137,900	146,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-9,700	132,100	-618,800	345,500	251,800	259,300	328,900	-164,700	16,500	-157,100	768,000	532,800	757,800	521,600	1,224,000	750,500	710,900	666,500	706,600	662,400	784,200	186,100	897,000	664,400	848,900	737,000	443,800	828,976	653,837	784,975	164,622	484,524	637,632	448,588	547,215	351,107	695,943	604,850	557,580	436,905	456,071	653,025	741,025	301,608
Other Operating Expenses	1,171,000	5,274,000	6,308,700	5,275,300	4,337,200	5,248,000	5,003,500	4,797,100	4,387,700	4,908,400	4,963,600	4,660,800	3,740,100	4,491,300	6,276,700	3,523,400	3,613,200	3,820,800	3,818,900	3,646,700	3,523,700	3,183,800	3,974,000	2,900,300	3,420,500	2,921,800	3,120,900	2,995,766	3,082,808	3,215,388	4,190,163	3,373,910	3,285,603	3,167,010	3,579,412	2,783,136	2,833,229	2,457,590	2,943,494	2,738,827	2,436,539	2,499,737	2,785,870	2,352,144
Reconciled Depreciation	-	750,800	838,800	749,500	740,500	747,100	767,600	790,800	784,000	737,000	735,300	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling General Administrative	2,533,300	2,563,800	2,525,900	2,550,800	2,348,000	2,390,000	2,197,700	2,244,100	2,147,200	2,140,200	2,010,900	1,926,000	1,750,100	1,935,800	2,044,500	1,783,900	1,596,900	1,721,200	2,229,300	1,584,400	1,518,400	1,434,000	1,771,200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax Provision	-22,400	-43,100	-407,100	31,000	74,000	79,500	1,214,700	-58,100	-34,100	-121,500	-121,700	178,300	242,300	118,900	301,100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	-	4,354,100	4,831,500	3,987,000	3,913,200	3,963,300	3,180,200	3,945,800	3,708,800	3,421,000	3,681,800	3,364,600	3,113,400	3,188,700	4,594,300	2,803,800	2,922,300	2,718,600	2,752,600	2,612,500	2,729,200	2,724,200	2,800,000	2,216,200	2,502,100	2,380,000	2,436,900	2,151,509	2,180,323	2,391,696	2,301,845	2,099,423	2,097,413	2,122,453	2,338,819	1,872,523	1,956,554	1,704,527	1,937,641	1,653,056	1,568,908	1,658,012	1,570,551	1,472,216
Total Other Income Expense Net	-	-135,100	-234,100	39,300	-65,900	-19,600	-464,600	-54,100	23,200	-178,600	-169,900	-26,000	-103,900	-59,600	-169,600	-5,900	-2,500	-85,900	42,200	18,200	-43,600	-48,200	-68,300	21,400	-112,500	-154,500	17,700	-168,352	-159,910	-277,547	361,437	-178,910	-164,704	-160,718	-42,489	-152,360	-173,658	-266,586	-103,458	-212,300	-119,540	-215,441	-219,994	-41,703
Total Revenue	6,139,600	5,406,100	5,689,900	5,620,800	4,589,000	5,507,300	5,332,400	4,632,400	4,404,200	4,751,300	5,731,600	5,193,600	4,497,900	5,012,900	7,500,700	4,273,900	4,324,100	4,487,300	4,525,500	4,309,100	4,307,900	3,369,900	4,871,000	3,564,700	4,269,400	3,658,800	3,564,700	3,824,742	3,736,645	4,000,363	4,354,785	3,858,434	3,923,235	3,615,598	4,126,627	3,134,243	3,529,172	3,062,440	3,501,074	3,175,732	2,892,610	3,152,762	3,526,895	2,653,752

Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue	21,406,900
Cost of Revenue	-4,474,200
Gross Profit	16,932,700	16,932,700

Operating Income (+$)
Gross Profit	16,932,700
Operating Expense	-16,694,900
Operating Income	237,800	237,800

Operating Expense (+$)
Research Development	-
Selling General Administrative	9,814,900
Selling And Marketing Expenses	-
Operating Expense	16,694,900	9,814,900

Net Interest Income (+$)
Interest Income	568,100
Interest Expense	-568,100
Net Interest Income	-568,100	0

Pretax Income (+$)
Operating Income	237,800
Net Interest Income	-568,100
Other Non-Operating Income Expenses	-
Income Before Tax (EBT)	-42,500	518,100 EBIT - interestExpense = -42,500 -42,500 748,200
Interest Expense	568,100
Earnings Before Interest and Taxes (ebit)	525,600	525,600
Earnings Before Interest and Taxes (ebitda)	3,601,500

After tax Income (+$)
Income Before Tax	-42,500
Tax Provision	--222,600
Net Income From Continuing Ops	180,100	180,100
Net Income	180,100
Net Income Applicable To Common Shares	180,100

Non-recurring Events
Discontinued Operations	-
Extraordinary Items	-
Effect of Accounting Charges	-
Other Items	-
Non Recurring	-
Other Operating Expenses	21,169,100
Total Other Income/Expenses Net	-280,300	568,100